Nottingham, UK-based clinical research organisation (CRO) XenoGesis has appointed Peter White as Director of Bioanalytical Business Development to further strengthen its growing DMPK team.
An experienced analytical project manager, White brings almost 20 years combined Drug Metabolism and Pharmacokinetic (DMPK) experience gained through working for CROs, as a consultant and with large pharma companies in both the Discovery and Development areas.
With a speciality in mass spectrometry and bioanalysis, White has used his expertise in both large and small molecule analysis to deliver pre-clinical and clinical bioanalytical support to numerous drug projects.
Commenting on the appointment, Managing Director, Richard Weaver said: 'I am delighted to welcome Peter to the team. He will be vital in helping XenoGesis to further enhance the analytical capabilities and experience within the business. He brings with him an extensive and varied background of method development skills in both large and small molecules that will increase the range of options available to us when offering expert DMPK services to our clients.'
